Virion Therapeutics Unveils Promising HBV Treatment at CROI Conference
Is the global fight against chronic hepatitis B (CHB) finally turning a corner? Virion Therapeutics, LLC, a clinical-stage biotechnology company, is making significant strides with its novel T cell-based immunotherapy, VRON-0200. At the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, CO, the company announced that a single intramuscular dose of VRON-0200 has shown the ability to re-awaken durable HBV-specific immunity in the majority of chronically HBV-infected patients, with sustained HBsAg declines through Day 360.
Key Insights at a Glance
- VRON-0200: A single intramuscular dose of VRON-0200 has demonstrated the ability to re-awaken durable HBV-specific immunity in chronically HBV-infected patients.
- Safety and Tolerability: VRON-0200 has shown an ongoing favorable safety and tolerability profile.
- Combination Therapy: VRON-0200 exhibits rapid and profound synergy when combined with antigen-lowering antiviral agents.
- Future Potential: The “Spark and Fan” model could shorten combination treatment regimens and expand to other populations, including those with higher baseline HBsAg levels and co-infected patients.
The Unmet Need for HBV Functional Cure
Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a significant global health issue, with an estimated 254 million people infected worldwide and 1.1 million deaths annually from HBV-related liver complications. Current treatments require lifelong antiviral therapy, and once treatment is discontinued, viral rebound typically occurs. This unmet medical need highlights the critical importance of immune modulators like VRON-0200, which can restore a patient’s own immune responses against the virus, potentially leading to a functional cure.
Why the Window for Action Is Closing Fast
Just as a wildfire needs to be contained before it spreads, Virion Therapeutics is racing against the clock to develop a functional cure for chronic HBV. The company’s VRON-0200 has shown promising results in re-awakening durable HBV-specific immunity, with sustained HBsAg declines through Day 360. Dr. Sue Currie, PhD, commented, “We are now at a pivotal point in the development of potential functional cures for chronic HBV, with exciting progress being made.” The next steps include the Phase 2b SPARK-B trial, which will evaluate VRON-0200 in combination with investigational antivirals, aiming to shorten treatment regimens and expand to other populations.
Virion Therapeutics Mobilizes for a Functional Cure
Virion Therapeutics, LLC is committed to advancing its novel T cell-based immunotherapy, VRON-0200, to address the unmet need for a functional cure in chronic HBV. The company’s lead program has demonstrated a favorable safety and tolerability profile, with durable clinical activity and the potential to prevent the need for rescue medications after treatment discontinuation. Dr. Andrew Luber, Pharm.D., CEO of Virion, stated, “VRON-0200, with its convenient single i.m. administration and potential for increased accessibility, is ideal for global public health initiatives.” The Phase 2b SPARK-B trial is in development, and the company is also exploring the benefits of CPM for other chronic viral diseases and advanced solid tumors.
Future Outlook
Like a lighthouse guiding ships through treacherous waters, Virion Therapeutics is illuminating the path toward a functional cure for chronic HBV. The company’s VRON-0200 has shown significant promise, with sustained and improving anti-HBV responses up to one year following a single dose. The upcoming Phase 2b SPARK-B trial will further evaluate VRON-0200’s potential as a foundational backbone agent in combination with investigational antivirals, aiming to improve functional cure rates and expand treatment options for a broader patient population.
Conclusion
The announcement from Virion Therapeutics marks a significant step forward in the fight against chronic hepatitis B. By re-awakening durable HBV-specific immunity and demonstrating a favorable safety profile, VRON-0200 has the potential to transform the treatment landscape and improve outcomes for millions of patients worldwide. Join the conversation in the comments below.
About Chronic Hepatitis B
Despite a preventative vaccine, cases of chronic hepatitis B (CHB) continue to rise, with an estimated 254 million persons infected worldwide and 1.1 million deaths per year from HBV-related liver complications. Chronic HBV remains a global health issue with a high unmet medical need since there is no cure available.
The current standard of care requires lifelong antiviral therapy to maintain control of the virus. Current and investigational HBV Functional Cure treatments have been limited by their inability to restore a patient’s own immune responses against the virus. As a result, once treatment is discontinued, and the antiviral agents are no longer present, viral rebound typically occurs. As a result, immune modulators are now considered necessary for future cure treatment strategies.
About VRON-0200
VRON-0200 is an investigational therapeutic immunotherapy designed with the goal of providing a functional cure for chronic HBV infection. Clinical data from an ongoing Phase 1b trial have shown VRON-0200 to be safe and well tolerated, and, when given as a single intramuscular dose, was immunogenic, and able to “Spark” anti-HBV activity in chronically HBV-infected patients on nucleos(t)ide therapy alone, and, also, when given with combination antiviral therapies. These results suggest the potential of VRON-0200 to be the key backbone immune modulator for HBV functional cure treatments.
About Virion Therapeutics (Virion)
Virion Therapeutics, LLC is a clinical-stage company developing novel immunotherapies that utilize proprietary checkpoint modifiers to enhance/restore, broaden, and elicit sustained immune responses, with the goal to cure cancer and chronic infectious diseases. Virion’s pipeline now includes its lead VRON-0200 clinical program, and several additional IND-enabling programs, such as its VRON-0300 oncology program for advanced solid tumors, leveraging its proprietary platform technologies.
Source link: https://www.businesswire.com/
